Skip to content

NHS Contract and Income

Accounting for Pharmacy First and NHS Service Income: The Separate Revenue Line You Should Be Tracking

11 November 2026 · 6 min read

Get in touch

Pharmacy First income: the short answer

Pharmacy First income is a growing, separately accounted revenue line under the NHS Community Pharmacy Contractual Framework. It has its own fee structure and thresholds, and it is paid as a remuneration fee, not as a Drug Tariff reimbursement. It must be booked as a distinct line in your management accounts. Merging it into a single NHS income total means you cannot see how it is performing, cannot benchmark it, and cannot manage it. The short rule: dispensing reimbursement and service income are two different things, and your accounts should show both.

Want this checked against your specific situation?

Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.

We'll only use your details to respond to your enquiry. We don't pass them to any other firm. See our Privacy Policy.

Where NHS service income sits in your income

Pharmacy income is contract-driven, not till-driven. Under the Community Pharmacy Contractual Framework, income has two broad components:

  • Reimbursement, which covers the ingredient cost of dispensed medicines at Drug Tariff prices. The Tariff price for the dispensing month is what you get, whatever you paid the wholesaler, and DHSC sets Category M prices each quarter.
  • Remuneration, which covers fees and service payments. This includes the essential and advanced service payments that sit alongside dispensing, and it is where Pharmacy First income sits.

This distinction matters because the two components behave differently, are calculated differently, and are paid under different mechanisms. Treating total NHSBSA receipts as a single number collapses that structure and leaves you without the information you need to understand your own business.

Why service income is a separate revenue line

Pharmacy First and the other advanced services sit on the remuneration side of pharmacy income. For 2026/27 the Pharmacy First budget was folded into the contract's £3.636 billion total, and the settlement funds pharmacist independent prescribing from autumn 2026 (CPCF letter for 2026 to 2027). As your consultation volume rises and the range of commissioned services widens, this line grows with it.

Service income has its own fee structure and thresholds, distinct from the Drug Tariff arithmetic that sets dispensing reimbursement. It is paid per service provided or per claim submitted, not as a reimbursement of ingredient cost. The two income streams respond to different levers: dispensing volume, product mix and Drug Tariff movements drive reimbursement; consultation volume and service delivery drive service income.

Keeping them on separate lines is not a bookkeeping preference. It is the only way to see which is growing, which is under pressure, and where management attention belongs.

How the fee structure differs from dispensing

Feature Dispensing reimbursement NHS service income (Pharmacy First and similar)
What it pays for Ingredient cost of dispensed medicines Clinical services provided under commission
How it is calculated Drug Tariff prices, Category M, endorsements Fee per service or per claim, under its own fee structure
What drives volume Prescription volume and product mix Consultation volume and commissioned service scope
Payment cycle FP34 monthly submission: NHSBSA advances its estimate of the whole claim around the 10th of the following month and squares it up roughly two months after you submit Pharmacy First activity is in the same advance through the average item value; consultation fees for named services (hypertension case-finding, contraception, flu and Covid-19 vaccination) are paid on the advance date (Drug Tariff Part I Clause 5C); reconcile claims submitted against payments received
VAT treatment Zero-rated (dispensing by registered pharmacist against prescription) Can be exempt or standard-rated depending on the service; must be mapped separately (see VAT note below)
CPCF source CPCF reimbursement schedule CPCF remuneration schedule

The fees are set in each year's contract settlement. For 2026/27 a Pharmacy First clinical pathway consultation earns £17, and the fixed payments "remain at £500 for contractors delivering 20 to 29 consultations in a month and £1,000 for those delivering 30 consultations or more" (CPCF letter for 2026 to 2027, 29 May 2026). They can change next year, so check the current letter. What matters for the accounts is that the structure exists, that it's separate from Drug Tariff arithmetic, and that your bookkeeping reflects that separation.

How it books versus dispensing income

The practical accounting split is straightforward. In a well-structured set of pharmacy management accounts, the income section shows at minimum:

  1. Dispensing reimbursement: the Drug Tariff recovery for ingredient costs, reconciled against FP34 submissions.
  2. NHS service income: Pharmacy First and other commissioned service fees, reconciled against claims submitted and NHSBSA payment statements.
  3. OTC retail and private sales: standard-rated counter sales, tracked separately because the VAT treatment differs from both lines above.

Some pharmacies add a fourth line for private services (private travel health, private prescriptions and so on) where that income is material. The point is not that there must be exactly three lines; it is that lumping any two together loses the management information each line carries.

Reconciliation works differently for each line. Dispensing reimbursement is reconciled by matching FP34 submissions to the NHSBSA payment schedule, tracking each month's advance, paid about ten days after the month ends, against the reconciliation that settles it two months after you submit (see the how the FP34 payment cycle works post for the cash-flow mechanics). Service income is reconciled by matching claims submitted for Pharmacy First consultations against the remuneration payments that follow. These are separate reconciliation processes, and running them together creates errors in both.

The VAT question, briefly

Dispensing is zero-rated under VAT Notice 701/57. Service income is not automatically zero-rated: services supplied by pharmacists can be exempt or standard-rated, and the treatment depends on the nature of the service. Medicines supplied under the Pharmacy First patient group directions carry a temporary zero rate, in force since 9 October 2023 for supplies made before 1 April 2027 (SI 2023/1006); beyond that date it depends on what HM Treasury and HMRC publish next. This is a material distinction for input VAT recovery and for the pharmacy's partial exemption position. The accounting and VAT treatment of NHS service income is covered in detail in the VAT on private services and Pharmacy First income post.

Why tracking it separately is a management-accounting job

The management-accounting case for separate tracking is simple: you cannot benchmark or grow a line you cannot see.

Service income as a share of total NHS income varies significantly across pharmacies. Some are early in delivering Pharmacy First; others are running it at high volume. Without a separate line in the accounts, a pharmacy owner cannot answer basic questions about their own business: Is service income growing? At what rate? How does it compare with pharmacies of similar dispensing volume? Is the consultation capacity being used efficiently?

These questions feed directly into margin analysis. A pharmacy that combines reimbursement and service income into one number cannot separate the margin behaviour of each. Dispensing margin is driven by Drug Tariff mechanics and Category M movements. Service income margin is driven by the cost of delivering the service (staff time, consumables, capacity). The two are managed differently, and mixing them obscures both.

Benchmarking also depends on clean income lines. Cross-pharmacy comparisons are only valid when the same definitions are used. Mixing income types produces comparisons that are not like-for-like and can mask real performance gaps or strengths.

Getting your NHS income lines right

The first step is making sure your chart of accounts has the right income categories. If your accounts currently show a single NHS income line, separating dispensing reimbursement from service income is a one-time restructuring exercise that pays for itself in the clarity it creates.

The second step is building reconciliation routines that match each income line to the correct NHSBSA statements and payment schedules. This is not the same process for each line, and trying to run one reconciliation across both creates errors.

The third step is using the separated lines for benchmarking. If you are comparing your pharmacy against sector averages or against your own prior periods, the comparison is only useful if the definitions match. A benchmarking exercise that mixes income types produces numbers that are not comparable with anything.

If your current accounts don't reflect the distinction between dispensing reimbursement and service income, the pharmacy benchmarking and margin analysis service is the right starting point: it structures the income lines correctly, runs the reconciliations, and gives you the benchmarks to see where each line is performing relative to similar pharmacies.

England only. The CPCF and Pharmacy First framework described here are England's NHS contract; the Drug Tariff also covers Wales. Scotland, Wales and Northern Ireland operate under different contract arrangements. If your pharmacy operates outside England, the income structure and fee frameworks will differ.

Frequently asked questions

Pharmacy First income is a remuneration payment under the NHS Community Pharmacy Contractual Framework, paid under its own fee structure. It should be recorded as a separate revenue line in the management accounts, distinct from Drug Tariff reimbursement, so that each income stream can be tracked and benchmarked independently.

Yes. Dispensing reimbursement and NHS service income behave differently, follow different payment structures, and carry different VAT treatments. Merging them into one 'NHS income' line makes it impossible to identify how each is performing or growing.

Pharmacy First is paid as a remuneration fee under the Community Pharmacy Contractual Framework, not as a Drug Tariff reimbursement. For 2026/27 a clinical pathway consultation earns £17, and the fixed payments stay at £500 for a month with 20 to 29 consultations and £1,000 for 30 or more (the CPCF letter for 2026 to 2027, 29 May 2026). The activity goes in with the month's FP34 declaration, so it's in NHSBSA's 100% advance through the average item value and then settled in the reconciliation.

The VAT treatment of NHS service income can differ from the zero-rating that applies to dispensing. Pharmacist services can be exempt or standard-rated depending on the service. Medicines supplied under the Pharmacy First patient group directions carry a temporary zero rate, in force since 9 October 2023 for supplies made before 1 April 2027. The detail is covered in the VAT on private services and Pharmacy First post.

You cannot manage or benchmark a revenue stream you cannot see. Tracking it separately lets you measure performance, compare against sector benchmarks, and spot whether the line is contributing as expected.

Related reading

Need help with your pharmacy finances?

Tell us about your situation and we will come back within 24 hours.

Step 1 of 2 · About you

Optional: a bit more detail (helps us prepare)